Search company, investor...

Predict your next investment

ID8 Investments company logo
Venture Capital
FINANCE | Investment Firms & Funds
id8investments.com

Investments

8

About ID8 Investments

ID8 Investments delivers an investment firm that focuses on partnering with next-generation consumer and technology companies.

Headquarters Location

New York, New York, 10013,

United States

Want to inform investors similar to ID8 Investments about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest ID8 Investments News

Synchron Raises $75M Series C Led by ARCH Venture Partners to Advance Endovascular Brain-Computer Interface

Dec 15, 2022

Top-tier investor syndicate includes new investors ARCH Venture Partners, Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X, with follow on participation from existing investors including Khosla Ventures, NeuroTechnology Investors, METIS, Forepont Capital Partners, ID8 Investments, Shanda Group and University of Melbourne. Funds will accelerate product development, facilitate commencement of a pivotal clinical trial, and advance Synchron towards a first-in-class BCI market approval for the treatment of paralysis. Download Loading media player... Stentrode™ is implanted within the motor cortex of the brain via the jugular vein in an endovascular procedure. Stentrode™ is implanted within the motor cortex of the brain via the jugular vein in an endovascular procedure. December 15, 2022 08:00 AM Eastern Standard Time NEW YORK--( BUSINESS WIRE )-- Synchron , the endovascular brain-computer interface (BCI) company, announced today an oversubscribed $75 million Series C financing round led by ARCH Venture Partners. Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors. Existing investors, including Khosla Ventures, NeuroTechnology Investors, METIS, Forepont Capital Partners, ID8 Investments, Shanda Group and University of Melbourne participated in the round. The Series C funding brings the total amount raised since inception to $145 million. The funding will accelerate development of Synchron’s first platform product (Synchron Switch™ BCI), and launch a pivotal clinical trial. Ari Nowacek from ARCH Venture Partners will join Synchron’s Board of Directors, and ARCH Co-Founder and Managing Director Robert Nelsen will join as Board Observer. “We have an opportunity to deliver a first-in-class commercial BCI. The problem of paralysis is much larger than people realize. 100 million people worldwide have upper limb impairment,” said Tom Oxley, M.D., Ph.D., CEO & Founder, Synchron. “We are extremely excited to work with ARCH and this world-class syndicate to bring this technology to the people who need it.” “At ARCH, our approach has always been to pair great science and technology with remarkable teams to build disruptive companies. The technology we witnessed at Synchron is helping people with previously untreatable conditions regain connection to the world. It is an exciting time for neurotechnology,” said ARCH Co-Founder and Managing Director Robert Nelsen. The Synchron Switch™ brain computer interface is implanted in the blood vessel on the surface of the motor cortex of the brain via the jugular vein, through a minimally-invasive endovascular procedure. Once implanted, it is designed to detect and wirelessly transmit motor intent out of the brain, restoring a capability for severely paralyzed patients to control personal devices with hands-free point-and-click. Synchron has an ongoing US clinical trial, COMMAND, that assesses the impact on daily tasks such as texting, emailing, online shopping, and telehealth services. The FDA granted Breakthrough Device designation to Synchron in August 2020 and an Investigational Device Exemption in July 2021. The first US patient was implanted in July 2022 at Mount Sinai in New York. View Synchron CEO 2022 TED Talk , “A brain implant that turns your thoughts into text.” About Synchron Synchron is a clinical-stage endovascular brain computer interface (BCI) company. Since 2012, the company has been developing a BCI platform that avoids the need for open brain surgery by using a minimally-invasive procedure. The Synchron Switch™ BCI received FDA Breakthrough Device Designation in 2020, and is currently in human clinical trials in the US and Australia. Synchron has been published in multiple peer-reviewed journals including Nature Biotechnology, Nature Biomedical Engineering and JNIS. Synchron is based in Brooklyn, New York with R&D facilities in Melbourne, Australia. For more information, visit www.synchron.com . Follow us on Twitter @synchroninc . Contacts

ID8 Investments Investments

8 Investments

ID8 Investments has made 8 investments. Their latest investment was in Betterment as part of their Series F on September 9, 2021.

CBI Logo

ID8 Investments Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/29/2021

Series F

Betterment

$60M

Yes

22

8/19/2021

Series A

Subscribe to see more

Subscribe to see more

10

8/11/2021

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

5/28/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

5/5/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/29/2021

8/19/2021

8/11/2021

5/28/2021

5/5/2021

Round

Series F

Series A

Seed VC - II

Series B

Seed VC

Company

Betterment

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$60M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

22

10

10

10

10

ID8 Investments Team

1 Team Member

ID8 Investments has 1 team member, including current Founding Partner, Adam Caplan.

Name

Work History

Title

Status

Adam Caplan

Founding Partner

Current

Name

Adam Caplan

Work History

Title

Founding Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.